Home > News > Positive ABRAXANE(TM) Phase III Trial in Metastatic Breast Cancer
September 24th, 2003
Positive ABRAXANE(TM) Phase III Trial in Metastatic Breast Cancer
Abstract:
American Pharmaceutical Partners, Inc.and American BioScience, Inc. (ABI) announced today that the
primary efficacy objective has been exceeded in the randomized, controlled Phase III clinical trial in 460 patients with metastatic breast cancer of ABRAXANE(TM) versus the Cremophor(R) solvent-based TAXOL. Initial
analysis of the data indicates that this solvent-free nanoparticle paclitaxel, ABRAXANE, resulted in higher anti-tumor activity and was not more toxic than TAXOL.
Source:
APP
Bookmark:
| Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||